CN114712385A - 硫酸葡聚糖的新用途 - Google Patents

硫酸葡聚糖的新用途 Download PDF

Info

Publication number
CN114712385A
CN114712385A CN202210555037.5A CN202210555037A CN114712385A CN 114712385 A CN114712385 A CN 114712385A CN 202210555037 A CN202210555037 A CN 202210555037A CN 114712385 A CN114712385 A CN 114712385A
Authority
CN
China
Prior art keywords
dextran sulfate
fibrosis
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210555037.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·布鲁斯
A·布鲁斯
A·瓦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TX Medic AB
Original Assignee
TX Medic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TX Medic AB filed Critical TX Medic AB
Publication of CN114712385A publication Critical patent/CN114712385A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN202210555037.5A 2015-07-30 2016-07-15 硫酸葡聚糖的新用途 Pending CN114712385A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1551050-6 2015-07-30
SE1551050A SE539575C2 (en) 2015-07-30 2015-07-30 Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
PCT/SE2016/050720 WO2017018922A1 (en) 2015-07-30 2016-07-15 New use of dextran sulfate
CN201680044788.3A CN107921055A (zh) 2015-07-30 2016-07-15 硫酸葡聚糖的新用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680044788.3A Division CN107921055A (zh) 2015-07-30 2016-07-15 硫酸葡聚糖的新用途

Publications (1)

Publication Number Publication Date
CN114712385A true CN114712385A (zh) 2022-07-08

Family

ID=57884849

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210555037.5A Pending CN114712385A (zh) 2015-07-30 2016-07-15 硫酸葡聚糖的新用途
CN201680044788.3A Pending CN107921055A (zh) 2015-07-30 2016-07-15 硫酸葡聚糖的新用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680044788.3A Pending CN107921055A (zh) 2015-07-30 2016-07-15 硫酸葡聚糖的新用途

Country Status (11)

Country Link
US (1) US10478451B2 (https=)
EP (1) EP3328395B1 (https=)
JP (1) JP6837679B2 (https=)
CN (2) CN114712385A (https=)
BR (1) BR112018001942A2 (https=)
DK (1) DK3328395T3 (https=)
EA (1) EA034313B1 (https=)
ES (1) ES2882115T3 (https=)
HK (1) HK1246640A1 (https=)
SE (1) SE539575C2 (https=)
WO (1) WO2017018922A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212708A1 (en) * 2017-05-17 2018-11-22 Tx Medic Ab Treatment of glaucoma
ES2777836T3 (es) * 2017-05-17 2020-08-06 Tx Medic Ab Tratamiento del glaucoma
AU2018329430B2 (en) 2017-09-08 2024-05-02 Tx Medic Ab New use of dextran sulfate
US20190275212A1 (en) * 2018-03-09 2019-09-12 Carmeda Ab Processes for immobilising biological entities
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2011091167A2 (en) * 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
CN102973593A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗肝纤维化药物中的应用
CN103889445A (zh) * 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
CN106573012A (zh) * 2014-06-12 2017-04-19 Tx医生公司 平均分子量低于10000Da的硫酸葡聚糖用于诱导受试者中的血管新生的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
US20040224922A1 (en) 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
SE525461C3 (sv) * 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
WO2008134430A1 (en) * 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2011091167A2 (en) * 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
CN103889445A (zh) * 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
CN102973593A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗肝纤维化药物中的应用
CN106573012A (zh) * 2014-06-12 2017-04-19 Tx医生公司 平均分子量低于10000Da的硫酸葡聚糖用于诱导受试者中的血管新生的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
UIDO KRENNING 等: "("The Origin of Fibroblasts a nd Mecha nism of Cardiac Fibrosis"", 《JOURNAL OF CELLULAR PHYSIOLOGY》, vol. 225, 15 July 2010 (2010-07-15), pages 631 *
YARA BAN Z: "" Locally targeted cytoprotection with dextran su l fate attenuates experimental porcine myocardial ischaemia / r eperfus i on injury "", 《EUROPEA N HEART JOURNAL》, vol. 26, 29 July 2005 (2005-07-29), pages 2335 *

Also Published As

Publication number Publication date
US20180221403A1 (en) 2018-08-09
US10478451B2 (en) 2019-11-19
CN107921055A (zh) 2018-04-17
DK3328395T3 (da) 2021-08-09
JP6837679B2 (ja) 2021-03-03
SE539575C2 (en) 2017-10-17
HK1246640A1 (zh) 2018-09-14
SE1551050A1 (en) 2017-01-31
EP3328395A1 (en) 2018-06-06
ES2882115T3 (es) 2021-12-01
EA034313B1 (ru) 2020-01-28
WO2017018922A1 (en) 2017-02-02
EA201890212A1 (ru) 2018-06-29
EP3328395B1 (en) 2021-06-09
EP3328395A4 (en) 2018-06-20
JP2018521086A (ja) 2018-08-02
BR112018001942A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
CN114712385A (zh) 硫酸葡聚糖的新用途
JP6837835B2 (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2002540144A (ja) 心血管及び関連病理学治療のためのピリドキシン化合物の使用
US10925890B2 (en) Use of dextran sulfate
KR101965396B1 (ko) 피부의 노화 치료제
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN115429781A (zh) 鱼腥草素钠在制备防治应激性心肌病药物中的应用
JP2010521215A (ja) 組織の修復を促進する方法
CN113811313A (zh) 食管狭窄抑制剂
KR20240117782A (ko) 켈로이드 치료를 위한 피부 패치와 주사 치료제 조성물
WO2018205233A1 (zh) 多肽化合物在治疗急性胰腺炎中的应用
CN118370721A (zh) 液态金属微粒递送丹参酮iia用于治疗心肌梗死药物的应用
WO2024169694A1 (zh) 一种抗皮肤纤维化的药物
EP3920957A1 (de) Kardioprotektiver effekt des vasokonstriktion-inhibierenden faktors (vif)
Kim et al. Drug Elimination Kinetics in the Eye after Subconjunctival Delivery
JP2002538087A (ja) 薬学的調製物を製造するためのオロソムコイドの使用
EP3856249A1 (en) Treatment of myocardial infarction
SE1451120A1 (sv) Use of dextran sulfate for inducing angiogenesis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220708

RJ01 Rejection of invention patent application after publication